A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumours and HER2 Positive Circulating Tumour Cells.

Trial Profile

A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumours and HER2 Positive Circulating Tumour Cells.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Vinorelbine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Nov 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 02 Oct 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top